Literature DB >> 12639503

Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.

Yi-Min Zheng1, Kirk R Henne, Patrick Charmley, Richard B Kim, D Gail McCarver, Erwin T Cabacungan, Ronald N Hines, Allan E Rettie.   

Abstract

CYP4B1 isoforms from rodents and other common laboratory animals are involved in the bioactivation of a range of protoxins, including 2-aminofluorene, 4-ipomeanol, and valproic acid. However, an earlier study provided evidence for a human allele encoding a nonfunctional CYP4B1 enzyme due to a Pro427Ser transversion in the meander region of the protein. In the present study, the CYP4B1 gene from several racial groups, Caucasians, African-Americans, and Hispanics, and from six nonhuman primate species was genotyped using a PCR-Hinf1 restriction enzyme fragment length polymorphism assay or by direct sequencing. All human populations examined were found to possess only the Ser allele at codon 427 ((1279)TCT) and all of the nonhuman primate species possessed only the Pro (CCT) allele. Therefore, an inactivating (1279)C-->T mutation in the human CYP4B1 gene likely arose following divergence of the Homo and Pan clades. Amino acid sequence alignments revealed further that this key Pro residue is located two amino acid residues N-terminal to the distal Arg of a Glu-Arg-Arg triad thought to participate in heme binding and/or redox partner interactions. Mutation of the corresponding Arg424 residue in rabbit CYP4B1 to Leu, but not His, resulted in a loss of lauric acid hydroxylase activity and ability to generate a reduced-CO binding spectrum. These data provide additional evidence for the importance of this meander region Pro-X-Arg motif in CYP4B1 heme binding and catalytic function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639503     DOI: 10.1016/s0041-008x(02)00028-5

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

Review 1.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

2.  Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.

Authors:  Sharon K Krueger; Lisbeth K Siddens; Marilyn C Henderson; Eric A Andreasen; Robert L Tanguay; Clifford B Pereira; Erwin T Cabacungan; Ronald N Hines; Kristin G Ardlie; David E Williams
Journal:  Pharmacogenet Genomics       Date:  2005-04       Impact factor: 2.089

Review 3.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

4.  Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Authors:  K Roellecke; E L Virts; R Einholz; K Z Edson; B Altvater; C Rossig; D von Laer; K Scheckenbach; M Wagenmann; D Reinhardt; C M Kramm; A E Rettie; C Wiek; H Hanenberg
Journal:  Gene Ther       Date:  2016-05-19       Impact factor: 5.250

5.  Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol.

Authors:  Constanze Wiek; Eva M Schmidt; Katharina Roellecke; Marcel Freund; Mariko Nakano; Edward J Kelly; Wolfgang Kaisers; Vladimir Yarov-Yarovoy; Christof M Kramm; Allan E Rettie; Helmut Hanenberg
Journal:  Biochem J       Date:  2015-01-01       Impact factor: 3.857

Review 6.  Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.

Authors:  Mohammed Jarrar; Shalini Behl; Ganiraju Manyam; Hany Ganah; Mohammed Nazir; Reem Nasab; Khaled Moustafa
Journal:  Mol Biol Rep       Date:  2016-04-12       Impact factor: 2.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.